Connor Clark & Lunn Investment Management Ltd. Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 61,288 shares of the biotechnology company’s stock, valued at approximately $643,000.

A number of other institutional investors also recently modified their holdings of RGNX. nVerses Capital LLC increased its stake in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 3,720 shares during the period. Diversified Trust Co bought a new stake in REGENXBIO in the 2nd quarter valued at about $121,000. Arizona State Retirement System raised its stake in REGENXBIO by 20.6% during the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after buying an additional 1,997 shares during the period. Finally, SG Americas Securities LLC bought a new position in REGENXBIO in the third quarter worth approximately $146,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Insider Buying and Selling

In other news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company’s stock, valued at $114,101.46. This trade represents a 46.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 13.13% of the stock is currently owned by corporate insiders.

REGENXBIO Stock Up 4.8 %

Shares of NASDAQ RGNX opened at $10.01 on Friday. The company has a market capitalization of $495.90 million, a PE ratio of -1.99 and a beta of 1.23. The stock’s 50 day moving average price is $10.06 and its 200-day moving average price is $11.91. REGENXBIO Inc. has a twelve month low of $8.53 and a twelve month high of $28.80.

Analysts Set New Price Targets

RGNX has been the subject of several recent research reports. Morgan Stanley restated an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. HC Wainwright dropped their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Chardan Capital reissued a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $35.27.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.